Inhibition of monocyte chemotactic protein-1 sysnthesis by statins

Laboratory Investigation

Volumn 80, Issue 7, 2000, Pages 1095-1100

  Romano, Maria ^a   Diomede, Luisa ^a   Sironi, Marina ^d   Massimiliano, Lucia ^a   Sottocorno, Marcello ^d   Polentarutti, Nadia ^a   Guglielmotti, Angelo ^b   Albani, Diego ^a   Bruno, Alessandra ^a   Fruscella, Paolo ^a   Salmona, Mario ^d   Vecchi, Annunciata ^a   Pinza, Mario ^b   Mantovani, Alberto ^a,c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LEUKOCYTE MIGRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; STREPTOCOCCUS;

EID: 0033913583     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780115     Document Type: Article

References (36)

1. Anonymous (1994). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) [see comments]. Lancet 344:1383-1389.
2. Anonymous (1998). Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97:1440-1445.
3. Bhatnagar D (1998). Lipid-lowering drugs in the management of hyperlipidaemia. Pharmacol Ther 79:205-230.
4. Boring L, Gosling J, Cleary M, and Charo IF (1998). Decreased lesion formation in CCR2 -/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894-897.
5. Corsini A, Maggi FM, and Catapano AL (1995a) Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 31:9-27.
6. Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, and Paoletti R. (1995b) Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 76:21A-28A.
7. Corsini A, Pazzucconi F, Arnaboldi L, Pfister P, Fumagalli R, Paoletti R, and Sirtori CR (1998). Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 31:773-778.
8. Downs JR, Clarfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langerdorfer A, Stein EA, Kruyer W, and Gotto AM (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 279:1615-1622.
9. Goldstein JL and Brown MS (1990). Regulation of the mevalonate pathway. Nature 343:425-430.
10. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, and Rollins BJ (1998). Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2:275-281.
11. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Diaz C, Hernandez G, and Egido J (1998). 3-Hydroxy-3-methylglutaryl Coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 83:490-500.
12. Ikeda U and Shimada K (1999). Statins and monocytes. Lancet 353:2070.
13. Kim S-Y, Guijarro C, O'Donnel MP, Kasiske BL, Kim Y, and Keane WF (1995). Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin. Kidney Int 48:363-371.
14. Kita T, Browns MS, and Goldstein JL (1980). Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevilonin, a competitive inhibitor of the reductase. J Clin Invest 66:1094-1100.
15. Kluft C, de Maat MP, Gevers Leuven JA, Potter van Loon BJ, and Mohrschladt MF (1999). Statins and C-reactive protein. Lancet 353:1274.
16. Kurakata S, Kada M, Shimada Y, Komai T, and Nomoto K (1996). Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 34:51-61.
17. MacMahon S, Sharpe N, Gamble G, Hart H, Simes J, and White H (1998). Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: Results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 97:1784-1790.
18. Mantovani A, Bussolino F, and Introna M (1997). Cytokine regulation of endothelial cell function: From molecular level to the bed side. Immunol Today 18:231-239.
19. Ness GC, Eales S, Lopez D, and Zhao Z (1994). Regulation of 3-Hydroxy-3-methylglutaryl coenzyme A reductase gene expression by sterols and nonsterols in rat liver. Arch Biochem Biophys 308:420-425.
20. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, and Keane WF (1993). Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 91:83-87.
21. Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Diaz C, Hernandez G, and Egido J (1999). Atorvastatin reduces NF-kB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 147:253-261.
22. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson NB, and Sugerman AA (1990). Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 30:1128-1135.
23. Park YS, Guijarro C, Kim Y, Massy ZA, Keane WF, and O'Donnell MP (1998). Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 31:190-194.
24. Reape TJ and Groot PHE (1999). Chemokines and atherosclerosis. Atherosclerosis 147:213-225.
25. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, and Braunwald E (1998). Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98:839-844.
26. Rollins BJ (1997). Chemokines. Blood 90:909-928.
27. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, Faggioni R, Luini W, vanHinsbergh V, Sozzani S, Bussolino F, Poli V, Ciliberto G, and Mantovani A (1997). Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6:315-325.
28. Rosenson RS, Tangney CC, and Casey LC (1999). Inhibition of proinflammatory cytokine production by pravastatin [letter]. Lancet 353:983-984.
29. Ross R (1993). The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:801-809.
30. Sironi M, Pozzi P, Polentarutti N, Benigni F, Coletta I, Guglielmotti A, Milanese C, Ghezzi P, Vecchi A, Pinza M, and Mantovani A (1996). Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine. Cytokine 8:710-716.
31. Sironi M, Milanese C, Vecchi A, Polenzani L, Guglielmotti A, Coletta I, Landolfi C, Soldo L, Mantovani A, Pinza M (1997). Benzydamine inhibits the release of tumor necrosis factor-a and monocyte chemotactic protein-1 by Candida albicans-stimulated human peripheral blood cells. Int J Clin Lab Res 27:118-122.
32. Sozzani S, Locati M, Allavena P, Van Damme J, and Mantovani A (1996). Chemokines: A superfamily of chemotactic cytokines. Int J Clin Lab Res 26:69-82.
33. Takeya M, Yoshimura T, Leonard EJ, and Takahashi K (1993). Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol 24:534-539.
34. Terkeltaub R, Solan J, Barry M, Santoro D, and Bokoch GM (1994). Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells. J Leukoc Biol 55:749-755.
35. van Vliet AK, Negre-Aminou P, van Thiel GC., Bolhuis PA, and Cohen LH (1996). Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle. Biochem Pharmacol 52:1387-1392.
36. Vaughan C, Murphy MB, and Buckley BM (1996). Statins do more than just lower cholesterol. Lancet 348:1079-1082.